BAT Investor Conference Presentation Deck

World-Class Capability in Science and R&D 2x R&D spend since 2017 1,500 R&D specialists £4.1bn New Category revenue since 2017* * Representative 2017 basis with a full 12 months of US acquisition, Reynolds. ** First amongst leading tobacco and nicotine global companies 1st Launch of e-cig, nicotine salts, CBD vaping" BAT A BETTER TOMORROW Phase I COVID & Flu vaccine studies 20

View entire presentation